ReviewJournal of nanobiotechnology2026
Next-generation biomedical nanorobots: active design, intelligent control, and translational opportunities in regenerative and minimally invasive medicine.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomedical nanorobots represent an emerging class of active nanosystems that enable controlled navigation, sensing, and targeted intervention within complex biological environments. This review presents recent developments in nanorobot design, highlighting key material architectures, including inorganic, soft, hybrid, and biohybrid systems and their modular integration for biomedical functionality. Major propulsion and control strategies, such as chemical, magnetic, and acoustic actuation, are discussed alongside emerging capabilities in environmental sensing, swarm intelligence, and AI-assisted control. Applications in regenerative medicine and MIIs are examined, with emphasis on targeted drug delivery, tissue repair, and theranostic systems across diverse disease contexts. Despite promising preclinical progress, significant translational challenges remain, including biological interactions, long-term biosafety, manufacturing scalability, and regulatory uncertainty. Finally, we outline key research priorities, including the development of biodegradable systems, standardized evaluation frameworks, and integration with imaging and digital medicine, to facilitate the safe and effective clinical translation of nanorobotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.